FDA-cleared profile

syngo.CT Lung CAD

Siemens Healthcare GmbH · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Adjunctive CAD assistance to alert radiologists to regions of interest that may otherwise be overlooked during chest MDCT review; concurrent first-reader or second-reader use is permitted, followed by full radiologist review.

Clinical role
Concurrent first-reader support followed by full review, or second-reader support after the radiologist's initial read; the algorithm alerts to ROI candidates and does not provide its own display UI.
Images and patients
CT/CTA · Pulmonary nodules in the thorax, including solid and subsolid (part-solid and ground-glass) nodules.
Key limitation
Keep in mind: Validated nodule scope is solid nodules at least 3 mm and less than 30 mm and subsolid nodules at least 5 mm and less than 30 mm, including central or peripheral and round or irregular contours. Intravenous contrast is not established as a supported characteristic in the study comparison; the packet states full radiologist review remains required and the hosting application supplies the user interface.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Adjunctive CAD assistance to alert radiologists to regions of interest that may otherwise be overlooked during chest MDCT review; concurrent first-reader or second-reader use is permitted, followed by full radiologist review.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Pulmonary nodules in the thorax, including solid and subsolid (part-solid and ground-glass) nodules. Input: Chest MDCT from multivendor scanners, with 16 or more detector rows; the scan must cover the entire thorax from lung apices to bases, with cranio-caudal or caudal-cranial direction, 100-140 kVp, up to and including 2.5 mm slice thickness, and no reconstruction gaps. The packet describes Siemens, GE, Philips, and Toshiba scanner data and typical validated kernels.
  • Who uses it?Intended users: Radiologists and trained professionals evaluating the CAD output.
  • What does the software produce?Output: A list of nodule candidate locations sent to a visualization application or rendering component, which generates output image series with CAD marks superimposed on the input thoracic CT images.
  • What is its most important limitation?Key limitation: Validated nodule scope is solid nodules at least 3 mm and less than 30 mm and subsolid nodules at least 5 mm and less than 30 mm, including central or peripheral and round or irregular contours. Intravenous contrast is not established as a supported characteristic in the study comparison; the packet states full radiologist review remains required and the hosting application supplies the user interface.

Clinical takeaway. Clinical role: Adjunctive CAD assistance to alert radiologists to regions of interest that may otherwise be overlooked during chest MDCT review; concurrent first-reader or second-reader use is permitted, followed by full radiologist review.

Evidence takeaway. Evidence from the reviewed source record: The pivotal retrospective reader study had 20 readers review all 232 cases in both second-reader and concurrent-first-reader workflows; five expert radiologists reviewed consolidated marks. Reader-majority truthing with expert adjudication identified 143 cases with at least one true nodule and 89 without true nodules. All reported analysis endpoints were satisfactorily met and all readers showed significant improvement in detection of solid, part-solid, and ground-glass nodules in both workflows; no numeric sensitivity, specificity, AUC, PPV, NPV, or reader-delta result is provided in the packet text.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Adjunctive CAD assistance to alert radiologists to regions of interest that may otherwise be overlooked during chest MDCT review; concurrent first-reader or second-reader use is permitted, followed by full radiologist review.
  • Exact FDA submission
  • Checked 2026-09-09
Workflow role
Concurrent first-reader support followed by full review, or second-reader support after the radiologist's initial read; the algorithm alerts to ROI candidates and does not provide its own display UI.
  • Exact FDA submission
  • Checked 2026-09-09
Required input
Chest MDCT from multivendor scanners, with 16 or more detector rows; the scan must cover the entire thorax from lung apices to bases, with cranio-caudal or caudal-cranial direction, 100-140 kVp, up to and including 2.5 mm slice thickness, and no reconstruction gaps. The packet describes Siemens, GE, Philips, and Toshiba scanner data and typical validated kernels.
  • Exact FDA submission
  • Checked 2026-09-09
Output and clinician action
A list of nodule candidate locations sent to a visualization application or rendering component, which generates output image series with CAD marks superimposed on the input thoracic CT images.
  • Exact FDA submission
  • Checked 2026-09-09
Care setting
Screening and diagnostic chest CT reading workflows.
  • Exact FDA submission
  • Checked 2026-09-09
Intended users
Radiologists and trained professionals evaluating the CAD output.
  • Exact FDA submission
  • Checked 2026-09-09
Limitations
Validated nodule scope is solid nodules at least 3 mm and less than 30 mm and subsolid nodules at least 5 mm and less than 30 mm, including central or peripheral and round or irregular contours. Intravenous contrast is not established as a supported characteristic in the study comparison; the packet states full radiologist review remains required and the hosting application supplies the user interface.
  • Exact FDA submission
  • Checked 2026-09-09
Evidence summary
The pivotal retrospective reader study had 20 readers review all 232 cases in both second-reader and concurrent-first-reader workflows; five expert radiologists reviewed consolidated marks. Reader-majority truthing with expert adjudication identified 143 cases with at least one true nodule and 89 without true nodules. All reported analysis endpoints were satisfactorily met and all readers showed significant improvement in detection of solid, part-solid, and ground-glass nodules in both workflows; no numeric sensitivity, specificity, AUC, PPV, NPV, or reader-delta result is provided in the packet text.
  • Exact FDA submission
  • Checked 2026-09-09

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The pivotal retrospective reader study had 20 readers review all 232 cases in both second-reader and concurrent-first-reader workflows; five expert radiologists reviewed consolidated marks. Reader-majority truthing with expert adjudication identified 143 cases with at least one true nodule and 89 without true nodules. All reported analysis endpoints were satisfactorily met and all readers showed significant improvement in detection of solid, part-solid, and ground-glass nodules in both workflows; no numeric sensitivity, specificity, AUC, PPV, NPV, or reader-delta result is provided in the packet text.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K203258. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Chest MDCT from multivendor scanners, with 16 or more detector rows; the scan must cover the entire thorax from lung apices to bases, with cranio-caudal or caudal-cranial direction, 100-140 kVp, up to and including 2.5 mm slice thickness, and no reconstruction gaps. The packet describes Siemens, GE, Philips, and Toshiba scanner data and typical validated kernels.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-09 · FDA K203258: syngo.CT Lung CAD

  2. Routing

    Source context, not route validation: The algorithm sends candidate locations to a hosting visualization application such as syngo MM Oncology or a rendering component; syngo MM Oncology is deployed on syngo.via, which displays the CAD marks. The device has no standalone UI, and specific local PACS or RIS compatibility is not established.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-09 · FDA K203258: syngo.CT Lung CAD

  3. AI processing

    Source context, not route validation: The exact FDA package describes syngo.CT Lung CAD as an algorithm without its own user interface, incorporated in a hosting application (syngo MM Oncology) on the syngo.via hosting platform. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "The software device is an algorithm which does not have its own user interface component for displaying of CAD marks. The Hosting Application incorporating syngo.CT Lung CAD is responsible for implementing a user interface." … "Hosting Platform syngo.via (VB50) syngo.via (VB60)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K203258: syngo.CT Lung CAD

  4. Returned objects

    Source context, not route validation: A list of nodule candidate locations sent to a visualization application or rendering component, which generates output image series with CAD marks superimposed on the input thoracic CT images.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-09 · FDA K203258: syngo.CT Lung CAD

  5. Viewer/worklist/report

    Unresolved route: A list of nodule candidate locations sent to a visualization application or rendering component, which generates output image series with CAD marks superimposed on the input thoracic CT images.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-09 · FDA K203258: syngo.CT Lung CAD

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes syngo.CT Lung CAD as an algorithm without its own user interface, incorporated in a hosting application (syngo MM Oncology) on the syngo.via hosting platform. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The software device is an algorithm which does not have its own user interface component for displaying of CAD marks. The Hosting Application incorporating syngo.CT Lung CAD is responsible for implementing a user interface." … "Hosting Platform syngo.via (VB50) syngo.via (VB60)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The algorithm sends candidate locations to a hosting visualization application such as syngo MM Oncology or a rendering component; syngo MM Oncology is deployed on syngo.via, which displays the CAD marks. The device has no standalone UI, and specific local PACS or RIS compatibility is not established.
  • Exact FDA submission
  • Checked 2026-09-09
Security
Siemens Healthineers' corporate cybersecurity page states a Secure Development Lifecycle addressing pre-market and post-market phases for products under development and a range of existing offerings; a Cybersecurity Management Service maintaining a product security inventory (over 1,000 product versions and over 21,000 monitored software components) with security whitepapers, SBOMs and vulnerability assessments available to customers via teamplay Fleet; incident and vulnerability management channels; and that Siemens Healthineers AG maintains an independent certification of its global Cybersecurity Management System to ISO/IEC 27001:2022 extended by ISO/IEC 27701:2019, with the certificate referenced to the SGS directory. Vendor statement; no certificate or report was read.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own corporate-info page names Siemens Medical Solutions USA, Inc. (Malvern, PA), and its 2024 governance press release states Siemens Healthcare GmbH's business was transferred to Siemens Healthineers AG. Corporate program statement; exact-release scope is not established.

Monitoring
Siemens Healthineers' cybersecurity page states that its Cybersecurity Management Service maintains a product security inventory of over 1,000 product versions and over 21,000 monitored software components, with security whitepapers, SBOMs and vulnerability assessments delivered via teamplay Fleet, and that it operates incident and vulnerability management.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. The page names Siemens Healthineers generally and does not scope these commitments to any specific product release; exact-release scope is not established.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for syngo.CT Lung CAD; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K203258
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Anatomy
Pulmonary nodules in the thorax, including solid and subsolid (part-solid and ground-glass) nodules.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2021-03-31
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
17Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K203258 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K203258: syngo.CT Lung CAD

    U.S. Food and Drug Administration - Published 2021-03-31 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. syngo.CT Lung CAD model card (K203258)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

    Scope: anatomy

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K203258

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

  8. Siemens Healthineers: Cybersecurity

    Siemens Healthineers - Accessed 2026-10-26

    Scope: security

Research history

  1. K203258 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K254075

Synapse Lung Nodule AI

Fujifilm Corporation

Authorized purpose: Concurrent-reader aid for a radiologist detecting pulmonary nodules during review of chest CT examinations in the lung cancer screening population under screening protocols.

Modality
CT/CTA
Anatomy
Chest/lungs; pulmonary nodules
Decision
2026-05-27
FDA-cleared K251474

Median LCS (internal name) / eyonis LCS (trade name) (1.0)

Median Technologies

eyonis LCS is a concurrent-reading aid for radiologists that detects, localizes, and characterizes 4-30 mm solid and part-solid pulmonary nodules on low-dose chest CT images for high-risk lung cancer screening patients; it provides nodule measurements and malignancy scores and does not replace physician judgment.

Modality
CT/CTA
Anatomy
Chest/Lung
Decision
2026-02-06
FDA-cleared K251769

RevealAI-Lung

Precision Medical Ventures, Inc. Dba Revealdx

Authorized purpose: Characterization and relative cancer-risk assessment of incidentally detected pulmonary nodules 6-15 mm in adults, with use as one input to follow-up and clinical decision-making under published guidelines; not lung-cancer screening

Modality
CT/CTA
Anatomy
Pulmonary nodules in the lungs
Decision
2026-01-30

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history